Mentis Cura, an Icelandic-Norwegian health technology company, begins marketing in Japan through partnership with Nihon Medi-Physics out of Japan. The partnership is valued at over 112.4-million USD (14-billion ISK) over the next 10 years. The partnership will enable the core products to be marketed in Japan following successful clinical trials and government approval.
Founded in Iceland in 2004, Mentis Cura produces software for the diagnosis of central nervous system (CNS) disorders, like Alzheimer’s, ADHD, etc., through the use of EEG and artificial intelligence. Mentis Cura, though recently moved headquarters to Norway, conducts its research and development in Iceland.
Mentis Cura products have been in commercial use in Iceland for years, while entering the Italian market later in 2019.
Life science companies, such as medical device companies, incorporated in Iceland benefit from low corporate tax and encouraging financial incentives for the clinical trial R&D and commercial applications. To learn more, please visit Invest in Iceland.
Get in touch
For further information on the benefits of establishing a business in Iceland please feel free to contact us.